nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP3A4—bone cancer	0.852	1	CbGaD
Montelukast—SLCO2B1—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00191	0.0532	CbGpPWpGaD
Montelukast—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00167	0.0467	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00114	0.0319	CbGpPWpGaD
Montelukast—CYSLTR1—Endothelins—GNA11—bone cancer	0.00112	0.0312	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00109	0.0305	CbGpPWpGaD
Montelukast—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000965	0.0269	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00093	0.0259	CbGpPWpGaD
Montelukast—Otitis media—Epirubicin—bone cancer	0.000915	0.00816	CcSEcCtD
Montelukast—Laryngitis—Doxorubicin—bone cancer	0.000914	0.00816	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000907	0.00809	CcSEcCtD
Montelukast—Cramp muscle—Cisplatin—bone cancer	0.000907	0.00809	CcSEcCtD
Montelukast—Nasopharyngitis—Cisplatin—bone cancer	0.0009	0.00803	CcSEcCtD
Montelukast—Dermatitis atopic—Doxorubicin—bone cancer	0.00089	0.00795	CcSEcCtD
Montelukast—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000889	0.0248	CbGpPWpGaD
Montelukast—Pancreatitis—Cisplatin—bone cancer	0.000853	0.00761	CcSEcCtD
Montelukast—Otitis media—Doxorubicin—bone cancer	0.000847	0.00755	CcSEcCtD
Montelukast—Liver injury—Epirubicin—bone cancer	0.000847	0.00755	CcSEcCtD
Montelukast—Bone disorder—Methotrexate—bone cancer	0.000843	0.00752	CcSEcCtD
Montelukast—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.000808	0.0225	CbGpPWpGaD
Montelukast—Viral infection—Epirubicin—bone cancer	0.000789	0.00704	CcSEcCtD
Montelukast—Bone disorder—Epirubicin—bone cancer	0.000789	0.00704	CcSEcCtD
Montelukast—Liver injury—Doxorubicin—bone cancer	0.000783	0.00699	CcSEcCtD
Montelukast—Vasculitis—Methotrexate—bone cancer	0.00078	0.00696	CcSEcCtD
Montelukast—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000777	0.0217	CbGpPWpGaD
Montelukast—Neuropathy peripheral—Cisplatin—bone cancer	0.000761	0.00679	CcSEcCtD
Montelukast—Conjunctivitis—Cisplatin—bone cancer	0.000754	0.00673	CcSEcCtD
Montelukast—ALOX5—Eicosanoid Synthesis—PTGS2—bone cancer	0.000754	0.021	CbGpPWpGaD
Montelukast—Hepatobiliary disease—Cisplatin—bone cancer	0.000734	0.00655	CcSEcCtD
Montelukast—Viral infection—Doxorubicin—bone cancer	0.00073	0.00651	CcSEcCtD
Montelukast—Bone disorder—Doxorubicin—bone cancer	0.00073	0.00651	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—GRM1—bone cancer	0.000727	0.0203	CbGpPWpGaD
Montelukast—Hepatocellular injury—Epirubicin—bone cancer	0.000712	0.00636	CcSEcCtD
Montelukast—Urinary tract disorder—Cisplatin—bone cancer	0.000688	0.00614	CcSEcCtD
Montelukast—Connective tissue disorder—Cisplatin—bone cancer	0.000684	0.00611	CcSEcCtD
Montelukast—Urethral disorder—Cisplatin—bone cancer	0.000683	0.00609	CcSEcCtD
Montelukast—Neuropathy—Epirubicin—bone cancer	0.000669	0.00597	CcSEcCtD
Montelukast—Hepatocellular injury—Doxorubicin—bone cancer	0.000659	0.00588	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000651	0.0181	CbGpPWpGaD
Montelukast—Cardiac disorder—Cisplatin—bone cancer	0.000646	0.00577	CcSEcCtD
Montelukast—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.000638	0.0178	CbGpPWpGaD
Montelukast—Immune system disorder—Cisplatin—bone cancer	0.000629	0.00561	CcSEcCtD
Montelukast—Mediastinal disorder—Cisplatin—bone cancer	0.000628	0.0056	CcSEcCtD
Montelukast—Neuropathy—Doxorubicin—bone cancer	0.000619	0.00552	CcSEcCtD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000613	0.0171	CbGpPWpGaD
Montelukast—Muscle spasms—Cisplatin—bone cancer	0.000583	0.0052	CcSEcCtD
Montelukast—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000577	0.0161	CbGpPWpGaD
Montelukast—Eczema—Epirubicin—bone cancer	0.000575	0.00513	CcSEcCtD
Montelukast—Tremor—Cisplatin—bone cancer	0.000568	0.00507	CcSEcCtD
Montelukast—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000554	0.0155	CbGpPWpGaD
Montelukast—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000552	0.0154	CbGpPWpGaD
Montelukast—Eczema—Doxorubicin—bone cancer	0.000532	0.00475	CcSEcCtD
Montelukast—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00053	0.0148	CbGpPWpGaD
Montelukast—Irritability—Methotrexate—bone cancer	0.000527	0.00471	CcSEcCtD
Montelukast—Convulsion—Cisplatin—bone cancer	0.000525	0.00469	CcSEcCtD
Montelukast—Myalgia—Cisplatin—bone cancer	0.000516	0.00461	CcSEcCtD
Montelukast—Anxiety—Cisplatin—bone cancer	0.000514	0.00459	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000513	0.00457	CcSEcCtD
Montelukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000503	0.014	CbGpPWpGaD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000503	0.014	CbGpPWpGaD
Montelukast—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000498	0.00444	CcSEcCtD
Montelukast—Oedema—Cisplatin—bone cancer	0.000495	0.00442	CcSEcCtD
Montelukast—Anaphylactic shock—Cisplatin—bone cancer	0.000495	0.00442	CcSEcCtD
Montelukast—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000492	0.0137	CbGpPWpGaD
Montelukast—Infection—Cisplatin—bone cancer	0.000492	0.00439	CcSEcCtD
Montelukast—Nervous system disorder—Cisplatin—bone cancer	0.000485	0.00433	CcSEcCtD
Montelukast—Thrombocytopenia—Cisplatin—bone cancer	0.000485	0.00432	CcSEcCtD
Montelukast—Skin disorder—Cisplatin—bone cancer	0.000481	0.00429	CcSEcCtD
Montelukast—Asthma—Methotrexate—bone cancer	0.000478	0.00426	CcSEcCtD
Montelukast—Eosinophilia—Methotrexate—bone cancer	0.000473	0.00422	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—GNA11—bone cancer	0.000469	0.0131	CbGpPWpGaD
Montelukast—Pancreatitis—Methotrexate—bone cancer	0.000468	0.00418	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000466	0.00415	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000466	0.00415	CcSEcCtD
Montelukast—Nasopharyngitis—Epirubicin—bone cancer	0.000462	0.00413	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000456	0.00407	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000451	0.00402	CcSEcCtD
Montelukast—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000449	0.0125	CbGpPWpGaD
Montelukast—Asthma—Epirubicin—bone cancer	0.000447	0.00399	CcSEcCtD
Montelukast—Influenza—Epirubicin—bone cancer	0.000447	0.00399	CcSEcCtD
Montelukast—Paraesthesia—Cisplatin—bone cancer	0.000444	0.00396	CcSEcCtD
Montelukast—Upper respiratory tract infection—Methotrexate—bone cancer	0.000444	0.00396	CcSEcCtD
Montelukast—Eosinophilia—Epirubicin—bone cancer	0.000442	0.00395	CcSEcCtD
Montelukast—Pancreatitis—Epirubicin—bone cancer	0.000438	0.00391	CcSEcCtD
Montelukast—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000432	0.012	CbGpPWpGaD
Montelukast—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000431	0.00384	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000431	0.00384	CcSEcCtD
Montelukast—Bronchitis—Epirubicin—bone cancer	0.00043	0.00383	CcSEcCtD
Montelukast—Pneumonia—Methotrexate—bone cancer	0.000428	0.00382	CcSEcCtD
Montelukast—Nasopharyngitis—Doxorubicin—bone cancer	0.000428	0.00382	CcSEcCtD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.000428	0.0119	CbGpPWpGaD
Montelukast—Gastrointestinal disorder—Cisplatin—bone cancer	0.000427	0.00381	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—bone cancer	0.000426	0.0038	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—bone cancer	0.000426	0.0038	CcSEcCtD
Montelukast—Infestation—Methotrexate—bone cancer	0.000426	0.0038	CcSEcCtD
Montelukast—Pain—Cisplatin—bone cancer	0.000423	0.00378	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—GRM4—bone cancer	0.000423	0.0118	CbGpPWpGaD
Montelukast—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000422	0.00377	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000422	0.00377	CcSEcCtD
Montelukast—ALOX5—Arachidonic acid metabolism—PTGS2—bone cancer	0.000419	0.0117	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000419	0.0117	CbGpPWpGaD
Montelukast—Upper respiratory tract infection—Epirubicin—bone cancer	0.000415	0.00371	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—bone cancer	0.000414	0.00369	CcSEcCtD
Montelukast—Asthma—Doxorubicin—bone cancer	0.000414	0.00369	CcSEcCtD
Montelukast—Influenza—Doxorubicin—bone cancer	0.000414	0.00369	CcSEcCtD
Montelukast—Eosinophilia—Doxorubicin—bone cancer	0.000409	0.00365	CcSEcCtD
Montelukast—Pancreatitis—Doxorubicin—bone cancer	0.000405	0.00362	CcSEcCtD
Montelukast—CYSLTR1—Endothelins—JUN—bone cancer	0.000405	0.0113	CbGpPWpGaD
Montelukast—Hepatobiliary disease—Methotrexate—bone cancer	0.000403	0.00359	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—bone cancer	0.000402	0.00358	CcSEcCtD
Montelukast—Pneumonia—Epirubicin—bone cancer	0.000401	0.00358	CcSEcCtD
Montelukast—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.0004	0.0112	CbGpPWpGaD
Montelukast—Drowsiness—Epirubicin—bone cancer	0.000398	0.00356	CcSEcCtD
Montelukast—Infestation NOS—Epirubicin—bone cancer	0.000398	0.00356	CcSEcCtD
Montelukast—Infestation—Epirubicin—bone cancer	0.000398	0.00356	CcSEcCtD
Montelukast—Bronchitis—Doxorubicin—bone cancer	0.000398	0.00355	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000395	0.00352	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000394	0.011	CbGpPWpGaD
Montelukast—Body temperature increased—Cisplatin—bone cancer	0.000391	0.00349	CcSEcCtD
Montelukast—Neuropathy peripheral—Epirubicin—bone cancer	0.000391	0.00349	CcSEcCtD
Montelukast—Jaundice—Epirubicin—bone cancer	0.000388	0.00347	CcSEcCtD
Montelukast—Conjunctivitis—Epirubicin—bone cancer	0.000387	0.00346	CcSEcCtD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000386	0.0108	CbGpPWpGaD
Montelukast—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000384	0.00343	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—bone cancer	0.000382	0.00341	CcSEcCtD
Montelukast—Pharyngitis—Methotrexate—bone cancer	0.000379	0.00338	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—bone cancer	0.000377	0.00337	CcSEcCtD
Montelukast—Hepatobiliary disease—Epirubicin—bone cancer	0.000377	0.00336	CcSEcCtD
Montelukast—Epistaxis—Epirubicin—bone cancer	0.000376	0.00335	CcSEcCtD
Montelukast—Urethral disorder—Methotrexate—bone cancer	0.000375	0.00334	CcSEcCtD
Montelukast—Sinusitis—Epirubicin—bone cancer	0.000374	0.00334	CcSEcCtD
Montelukast—Pneumonia—Doxorubicin—bone cancer	0.000371	0.00331	CcSEcCtD
Montelukast—Drowsiness—Doxorubicin—bone cancer	0.000369	0.00329	CcSEcCtD
Montelukast—Infestation NOS—Doxorubicin—bone cancer	0.000369	0.00329	CcSEcCtD
Montelukast—Infestation—Doxorubicin—bone cancer	0.000369	0.00329	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—GRM1—bone cancer	0.000367	0.0102	CbGpPWpGaD
Montelukast—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000366	0.00326	CcSEcCtD
Montelukast—Hypersensitivity—Cisplatin—bone cancer	0.000365	0.00325	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—bone cancer	0.000361	0.00322	CcSEcCtD
Montelukast—Neuropathy peripheral—Doxorubicin—bone cancer	0.000361	0.00322	CcSEcCtD
Montelukast—Jaundice—Doxorubicin—bone cancer	0.000359	0.00321	CcSEcCtD
Montelukast—Rhinitis—Epirubicin—bone cancer	0.000359	0.0032	CcSEcCtD
Montelukast—Conjunctivitis—Doxorubicin—bone cancer	0.000358	0.0032	CcSEcCtD
Montelukast—Hepatitis—Epirubicin—bone cancer	0.000358	0.00319	CcSEcCtD
Montelukast—Hypoaesthesia—Epirubicin—bone cancer	0.000356	0.00318	CcSEcCtD
Montelukast—Asthenia—Cisplatin—bone cancer	0.000355	0.00317	CcSEcCtD
Montelukast—Pharyngitis—Epirubicin—bone cancer	0.000355	0.00317	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—bone cancer	0.000355	0.00317	CcSEcCtD
Montelukast—Urinary tract disorder—Epirubicin—bone cancer	0.000353	0.00315	CcSEcCtD
Montelukast—Connective tissue disorder—Epirubicin—bone cancer	0.000352	0.00314	CcSEcCtD
Montelukast—Urethral disorder—Epirubicin—bone cancer	0.000351	0.00313	CcSEcCtD
Montelukast—Hepatobiliary disease—Doxorubicin—bone cancer	0.000349	0.00311	CcSEcCtD
Montelukast—Epistaxis—Doxorubicin—bone cancer	0.000348	0.0031	CcSEcCtD
Montelukast—Sinusitis—Doxorubicin—bone cancer	0.000346	0.00309	CcSEcCtD
Montelukast—Immune system disorder—Methotrexate—bone cancer	0.000345	0.00308	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—bone cancer	0.000344	0.00307	CcSEcCtD
Montelukast—Diarrhoea—Cisplatin—bone cancer	0.000339	0.00302	CcSEcCtD
Montelukast—Erythema multiforme—Epirubicin—bone cancer	0.000338	0.00302	CcSEcCtD
Montelukast—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000335	0.00935	CbGpPWpGaD
Montelukast—Mental disorder—Methotrexate—bone cancer	0.000335	0.00299	CcSEcCtD
Montelukast—Cardiac disorder—Epirubicin—bone cancer	0.000332	0.00296	CcSEcCtD
Montelukast—Rhinitis—Doxorubicin—bone cancer	0.000332	0.00296	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000331	0.00924	CbGpPWpGaD
Montelukast—Hepatitis—Doxorubicin—bone cancer	0.000331	0.00295	CcSEcCtD
Montelukast—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000331	0.00923	CbGpPWpGaD
Montelukast—Hypoaesthesia—Doxorubicin—bone cancer	0.000329	0.00294	CcSEcCtD
Montelukast—Pharyngitis—Doxorubicin—bone cancer	0.000328	0.00293	CcSEcCtD
Montelukast—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000327	0.00912	CbGpPWpGaD
Montelukast—Urinary tract disorder—Doxorubicin—bone cancer	0.000327	0.00292	CcSEcCtD
Montelukast—Connective tissue disorder—Doxorubicin—bone cancer	0.000325	0.0029	CcSEcCtD
Montelukast—Urethral disorder—Doxorubicin—bone cancer	0.000324	0.00289	CcSEcCtD
Montelukast—Immune system disorder—Epirubicin—bone cancer	0.000323	0.00288	CcSEcCtD
Montelukast—Mediastinal disorder—Epirubicin—bone cancer	0.000322	0.00288	CcSEcCtD
Montelukast—Vomiting—Cisplatin—bone cancer	0.000315	0.00281	CcSEcCtD
Montelukast—Mental disorder—Epirubicin—bone cancer	0.000313	0.0028	CcSEcCtD
Montelukast—Erythema multiforme—Doxorubicin—bone cancer	0.000313	0.00279	CcSEcCtD
Montelukast—Rash—Cisplatin—bone cancer	0.000312	0.00278	CcSEcCtD
Montelukast—Dermatitis—Cisplatin—bone cancer	0.000312	0.00278	CcSEcCtD
Montelukast—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000308	0.0086	CbGpPWpGaD
Montelukast—Cardiac disorder—Doxorubicin—bone cancer	0.000307	0.00274	CcSEcCtD
Montelukast—Muscle spasms—Epirubicin—bone cancer	0.000299	0.00267	CcSEcCtD
Montelukast—Immune system disorder—Doxorubicin—bone cancer	0.000299	0.00267	CcSEcCtD
Montelukast—Mediastinal disorder—Doxorubicin—bone cancer	0.000298	0.00266	CcSEcCtD
Montelukast—Nausea—Cisplatin—bone cancer	0.000294	0.00262	CcSEcCtD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000294	0.00819	CbGpPWpGaD
Montelukast—Cough—Methotrexate—bone cancer	0.00029	0.00259	CcSEcCtD
Montelukast—Mental disorder—Doxorubicin—bone cancer	0.00029	0.00259	CcSEcCtD
Montelukast—Convulsion—Methotrexate—bone cancer	0.000288	0.00257	CcSEcCtD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000287	0.00802	CbGpPWpGaD
Montelukast—Agitation—Epirubicin—bone cancer	0.000286	0.00255	CcSEcCtD
Montelukast—Myalgia—Methotrexate—bone cancer	0.000283	0.00253	CcSEcCtD
Montelukast—Arthralgia—Methotrexate—bone cancer	0.000283	0.00253	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000281	0.00251	CcSEcCtD
Montelukast—Muscle spasms—Doxorubicin—bone cancer	0.000277	0.00247	CcSEcCtD
Montelukast—Palpitations—Epirubicin—bone cancer	0.000275	0.00246	CcSEcCtD
Montelukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000274	0.00763	CbGpPWpGaD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000272	0.00758	CbGpPWpGaD
Montelukast—Cough—Epirubicin—bone cancer	0.000272	0.00242	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—bone cancer	0.000272	0.00242	CcSEcCtD
Montelukast—Convulsion—Epirubicin—bone cancer	0.00027	0.00241	CcSEcCtD
Montelukast—Infection—Methotrexate—bone cancer	0.00027	0.00241	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—PTGS2—bone cancer	0.000267	0.00744	CbGpPWpGaD
Montelukast—Nervous system disorder—Methotrexate—bone cancer	0.000266	0.00238	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—bone cancer	0.000266	0.00237	CcSEcCtD
Montelukast—Arthralgia—Epirubicin—bone cancer	0.000265	0.00237	CcSEcCtD
Montelukast—Myalgia—Epirubicin—bone cancer	0.000265	0.00237	CcSEcCtD
Montelukast—Agitation—Doxorubicin—bone cancer	0.000265	0.00236	CcSEcCtD
Montelukast—Anxiety—Epirubicin—bone cancer	0.000264	0.00236	CcSEcCtD
Montelukast—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000264	0.00736	CbGpPWpGaD
Montelukast—Skin disorder—Methotrexate—bone cancer	0.000264	0.00235	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000263	0.00235	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—SMO—bone cancer	0.000258	0.00721	CbGpPWpGaD
Montelukast—Palpitations—Doxorubicin—bone cancer	0.000255	0.00227	CcSEcCtD
Montelukast—Oedema—Epirubicin—bone cancer	0.000254	0.00227	CcSEcCtD
Montelukast—Anaphylactic shock—Epirubicin—bone cancer	0.000254	0.00227	CcSEcCtD
Montelukast—Infection—Epirubicin—bone cancer	0.000252	0.00225	CcSEcCtD
Montelukast—Cough—Doxorubicin—bone cancer	0.000251	0.00224	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000251	0.007	CbGpPWpGaD
Montelukast—Convulsion—Doxorubicin—bone cancer	0.00025	0.00223	CcSEcCtD
Montelukast—Nervous system disorder—Epirubicin—bone cancer	0.000249	0.00222	CcSEcCtD
Montelukast—Thrombocytopenia—Epirubicin—bone cancer	0.000249	0.00222	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000247	0.00221	CcSEcCtD
Montelukast—Skin disorder—Epirubicin—bone cancer	0.000247	0.0022	CcSEcCtD
Montelukast—Insomnia—Methotrexate—bone cancer	0.000246	0.00219	CcSEcCtD
Montelukast—Myalgia—Doxorubicin—bone cancer	0.000245	0.00219	CcSEcCtD
Montelukast—Arthralgia—Doxorubicin—bone cancer	0.000245	0.00219	CcSEcCtD
Montelukast—Anxiety—Doxorubicin—bone cancer	0.000244	0.00218	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—bone cancer	0.000244	0.00218	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000244	0.00217	CcSEcCtD
Montelukast—Somnolence—Methotrexate—bone cancer	0.000241	0.00215	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—RGS1—bone cancer	0.000239	0.00667	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—GRM4—bone cancer	0.000239	0.00667	CbGpPWpGaD
Montelukast—Dyspepsia—Methotrexate—bone cancer	0.000239	0.00213	CcSEcCtD
Montelukast—Oedema—Doxorubicin—bone cancer	0.000235	0.0021	CcSEcCtD
Montelukast—Anaphylactic shock—Doxorubicin—bone cancer	0.000235	0.0021	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—bone cancer	0.000234	0.00209	CcSEcCtD
Montelukast—Fatigue—Methotrexate—bone cancer	0.000234	0.00209	CcSEcCtD
Montelukast—Infection—Doxorubicin—bone cancer	0.000234	0.00208	CcSEcCtD
Montelukast—Pain—Methotrexate—bone cancer	0.000232	0.00207	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000232	0.00207	CcSEcCtD
Montelukast—Nervous system disorder—Doxorubicin—bone cancer	0.000231	0.00206	CcSEcCtD
Montelukast—Thrombocytopenia—Doxorubicin—bone cancer	0.00023	0.00205	CcSEcCtD
Montelukast—Insomnia—Epirubicin—bone cancer	0.00023	0.00205	CcSEcCtD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000229	0.00639	CbGpPWpGaD
Montelukast—Skin disorder—Doxorubicin—bone cancer	0.000228	0.00204	CcSEcCtD
Montelukast—Paraesthesia—Epirubicin—bone cancer	0.000228	0.00204	CcSEcCtD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000226	0.0063	CbGpPWpGaD
Montelukast—Somnolence—Epirubicin—bone cancer	0.000226	0.00202	CcSEcCtD
Montelukast—Dyspepsia—Epirubicin—bone cancer	0.000224	0.002	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—bone cancer	0.000222	0.00198	CcSEcCtD
Montelukast—Gastrointestinal disorder—Epirubicin—bone cancer	0.000219	0.00196	CcSEcCtD
Montelukast—Fatigue—Epirubicin—bone cancer	0.000219	0.00196	CcSEcCtD
Montelukast—Pain—Epirubicin—bone cancer	0.000217	0.00194	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—RGS1—bone cancer	0.000217	0.00606	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—GRM4—bone cancer	0.000217	0.00606	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000217	0.00604	CbGpPWpGaD
Montelukast—Urticaria—Methotrexate—bone cancer	0.000216	0.00192	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—bone cancer	0.000215	0.00192	CcSEcCtD
Montelukast—Body temperature increased—Methotrexate—bone cancer	0.000215	0.00192	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000214	0.00191	CcSEcCtD
Montelukast—Insomnia—Doxorubicin—bone cancer	0.000213	0.0019	CcSEcCtD
Montelukast—Paraesthesia—Doxorubicin—bone cancer	0.000211	0.00188	CcSEcCtD
Montelukast—ALOX5—Metabolism—NDUFA12—bone cancer	0.000211	0.00589	CbGpPWpGaD
Montelukast—Somnolence—Doxorubicin—bone cancer	0.000209	0.00187	CcSEcCtD
Montelukast—Gastrointestinal pain—Epirubicin—bone cancer	0.000208	0.00185	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—GRM1—bone cancer	0.000207	0.00578	CbGpPWpGaD
Montelukast—Dyspepsia—Doxorubicin—bone cancer	0.000207	0.00185	CcSEcCtD
Montelukast—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000203	0.00181	CcSEcCtD
Montelukast—Fatigue—Doxorubicin—bone cancer	0.000203	0.00181	CcSEcCtD
Montelukast—Urticaria—Epirubicin—bone cancer	0.000202	0.0018	CcSEcCtD
Montelukast—Pain—Doxorubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Montelukast—Body temperature increased—Epirubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Montelukast—Abdominal pain—Epirubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Montelukast—Hypersensitivity—Methotrexate—bone cancer	0.0002	0.00179	CcSEcCtD
Montelukast—Asthenia—Methotrexate—bone cancer	0.000195	0.00174	CcSEcCtD
Montelukast—Gastrointestinal pain—Doxorubicin—bone cancer	0.000192	0.00172	CcSEcCtD
Montelukast—Pruritus—Methotrexate—bone cancer	0.000192	0.00171	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—GRM1—bone cancer	0.000188	0.00525	CbGpPWpGaD
Montelukast—Hypersensitivity—Epirubicin—bone cancer	0.000187	0.00167	CcSEcCtD
Montelukast—Urticaria—Doxorubicin—bone cancer	0.000187	0.00167	CcSEcCtD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000186	0.0052	CbGpPWpGaD
Montelukast—Body temperature increased—Doxorubicin—bone cancer	0.000186	0.00166	CcSEcCtD
Montelukast—Abdominal pain—Doxorubicin—bone cancer	0.000186	0.00166	CcSEcCtD
Montelukast—Diarrhoea—Methotrexate—bone cancer	0.000186	0.00166	CcSEcCtD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000186	0.00518	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000184	0.00513	CbGpPWpGaD
Montelukast—Asthenia—Epirubicin—bone cancer	0.000182	0.00163	CcSEcCtD
Montelukast—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000182	0.00507	CbGpPWpGaD
Montelukast—Pruritus—Epirubicin—bone cancer	0.00018	0.0016	CcSEcCtD
Montelukast—Dizziness—Methotrexate—bone cancer	0.00018	0.0016	CcSEcCtD
Montelukast—ALOX5—Metabolism—NT5C3A—bone cancer	0.000175	0.00488	CbGpPWpGaD
Montelukast—Diarrhoea—Epirubicin—bone cancer	0.000174	0.00155	CcSEcCtD
Montelukast—Hypersensitivity—Doxorubicin—bone cancer	0.000173	0.00155	CcSEcCtD
Montelukast—Vomiting—Methotrexate—bone cancer	0.000173	0.00154	CcSEcCtD
Montelukast—Rash—Methotrexate—bone cancer	0.000171	0.00153	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—bone cancer	0.000171	0.00153	CcSEcCtD
Montelukast—Headache—Methotrexate—bone cancer	0.00017	0.00152	CcSEcCtD
Montelukast—Asthenia—Doxorubicin—bone cancer	0.000169	0.00151	CcSEcCtD
Montelukast—Dizziness—Epirubicin—bone cancer	0.000168	0.0015	CcSEcCtD
Montelukast—Pruritus—Doxorubicin—bone cancer	0.000166	0.00148	CcSEcCtD
Montelukast—Vomiting—Epirubicin—bone cancer	0.000162	0.00144	CcSEcCtD
Montelukast—Nausea—Methotrexate—bone cancer	0.000161	0.00144	CcSEcCtD
Montelukast—Diarrhoea—Doxorubicin—bone cancer	0.000161	0.00144	CcSEcCtD
Montelukast—Rash—Epirubicin—bone cancer	0.00016	0.00143	CcSEcCtD
Montelukast—Dermatitis—Epirubicin—bone cancer	0.00016	0.00143	CcSEcCtD
Montelukast—Headache—Epirubicin—bone cancer	0.000159	0.00142	CcSEcCtD
Montelukast—Dizziness—Doxorubicin—bone cancer	0.000155	0.00139	CcSEcCtD
Montelukast—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000153	0.00426	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000151	0.00421	CbGpPWpGaD
Montelukast—Nausea—Epirubicin—bone cancer	0.000151	0.00135	CcSEcCtD
Montelukast—Vomiting—Doxorubicin—bone cancer	0.00015	0.00133	CcSEcCtD
Montelukast—Rash—Doxorubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Montelukast—Dermatitis—Doxorubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Montelukast—Headache—Doxorubicin—bone cancer	0.000147	0.00131	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000144	0.00403	CbGpPWpGaD
Montelukast—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000143	0.00398	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000141	0.00393	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000141	0.00393	CbGpPWpGaD
Montelukast—Nausea—Doxorubicin—bone cancer	0.00014	0.00125	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—GNA11—bone cancer	0.000134	0.00373	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—SMO—bone cancer	0.000133	0.0037	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000131	0.00364	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RGS1—bone cancer	0.000128	0.00358	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—GRM4—bone cancer	0.000128	0.00358	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.000123	0.00344	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—GNA11—bone cancer	0.000121	0.00338	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL3—bone cancer	0.000121	0.00338	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000119	0.00333	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000117	0.00327	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000116	0.00323	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—GRM1—bone cancer	0.000111	0.0031	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL3—bone cancer	0.00011	0.00307	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP3A4—bone cancer	9.86e-05	0.00275	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	9.73e-05	0.00271	CbGpPWpGaD
Montelukast—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	9.56e-05	0.00267	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NDUFA12—bone cancer	9.15e-05	0.00255	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NDUFA12—bone cancer	8.66e-05	0.00241	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.44e-05	0.00235	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.32e-05	0.00232	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.03e-05	0.00224	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.92e-05	0.00221	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SMO—bone cancer	7.84e-05	0.00219	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ENO2—bone cancer	7.66e-05	0.00214	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NT5C3A—bone cancer	7.58e-05	0.00211	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NT5C3A—bone cancer	7.17e-05	0.002	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—GNA11—bone cancer	7.17e-05	0.002	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—DHFR—bone cancer	7.11e-05	0.00198	CbGpPWpGaD
Montelukast—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.99e-05	0.00195	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.87e-05	0.00191	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.77e-05	0.00189	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ATF1—bone cancer	6.66e-05	0.00186	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GNA11—bone cancer	6.64e-05	0.00185	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL3—bone cancer	6.5e-05	0.00181	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP3A4—bone cancer	6.02e-05	0.00168	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.99e-05	0.00167	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NDUFA12—bone cancer	5.91e-05	0.00165	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TGFBR2—bone cancer	5.56e-05	0.00155	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IGF1R—bone cancer	5.23e-05	0.00146	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTP1—bone cancer	5.15e-05	0.00144	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NT5C3A—bone cancer	4.9e-05	0.00137	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NDUFA12—bone cancer	4.81e-05	0.00134	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.53e-05	0.00126	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.47e-05	0.00125	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NT5C3A—bone cancer	3.99e-05	0.00111	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KIT—bone cancer	3.79e-05	0.00106	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—BRAF—bone cancer	3.56e-05	0.000994	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—EGFR—bone cancer	3.45e-05	0.000963	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ENO2—bone cancer	3.32e-05	0.000926	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NDUFA12—bone cancer	3.17e-05	0.000885	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ENO2—bone cancer	3.14e-05	0.000876	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—DHFR—bone cancer	3.08e-05	0.000859	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MDM2—bone cancer	2.99e-05	0.000833	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—DHFR—bone cancer	2.91e-05	0.000813	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GNA11—bone cancer	2.88e-05	0.000803	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GNA11—bone cancer	2.72e-05	0.00076	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS2—bone cancer	2.67e-05	0.000744	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NT5C3A—bone cancer	2.63e-05	0.000733	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP3A4—bone cancer	2.61e-05	0.000728	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.6e-05	0.000725	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—JUN—bone cancer	2.6e-05	0.000724	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MMP9—bone cancer	2.53e-05	0.000704	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP3A4—bone cancer	2.47e-05	0.000689	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTP1—bone cancer	2.23e-05	0.000623	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ENO2—bone cancer	2.15e-05	0.000598	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTP1—bone cancer	2.11e-05	0.000589	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EGFR—bone cancer	2.04e-05	0.000569	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—DHFR—bone cancer	1.99e-05	0.000555	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GNA11—bone cancer	1.86e-05	0.000519	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ENO2—bone cancer	1.75e-05	0.000487	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—bone cancer	1.71e-05	0.000478	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP3A4—bone cancer	1.69e-05	0.00047	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.68e-05	0.000468	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—DHFR—bone cancer	1.62e-05	0.000452	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GNA11—bone cancer	1.51e-05	0.000422	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTP1—bone cancer	1.44e-05	0.000402	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP3A4—bone cancer	1.37e-05	0.000383	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.37e-05	0.000381	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTP1—bone cancer	1.17e-05	0.000327	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTGS2—bone cancer	1.16e-05	0.000323	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ENO2—bone cancer	1.15e-05	0.000321	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS2—bone cancer	1.09e-05	0.000305	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—DHFR—bone cancer	1.07e-05	0.000298	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GNA11—bone cancer	9.99e-06	0.000278	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTP1—bone cancer	7.74e-06	0.000216	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS2—bone cancer	7.47e-06	0.000208	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS2—bone cancer	6.08e-06	0.00017	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS2—bone cancer	4.01e-06	0.000112	CbGpPWpGaD
